These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30661177)

  • 1. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch.
    Xu H; Tong X; Mugundu G; Scott ML; Cook C; Arfvidsson C; Pease E; Zhou D; Lyne P; Al-Huniti N
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):65-74. PubMed ID: 30661177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
    Nishina T; Fujita T; Yoshizuka N; Sugibayashi K; Murayama K; Kuboki Y
    BMJ Open; 2022 Oct; 12(10):e055718. PubMed ID: 36270753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
    Chiu YL; Carlson DM; Pradhan RS; Ricker JL
    Clin Ther; 2013 Nov; 35(11):1770-7. PubMed ID: 24094464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
    Fabre MA; Fuseau E; Ficheux H
    J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.
    Kuester K; Kovar A; Lüpfert C; Brockhaus B; Kloft C
    Clin Pharmacokinet; 2009; 48(7):477-87. PubMed ID: 19691369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
    Wilkins JJ; Vugmeyster Y; Dussault I; Girard P; Khandelwal A
    Adv Ther; 2019 Sep; 36(9):2414-2433. PubMed ID: 31278692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status.
    Baverel PG; Dubois VFS; Jin CY; Zheng Y; Song X; Jin X; Mukhopadhyay P; Gupta A; Dennis PA; Ben Y; Vicini P; Roskos L; Narwal R
    Clin Pharmacol Ther; 2018 Apr; 103(4):631-642. PubMed ID: 29243223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
    Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
    Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
    Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
    Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
    Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation.
    Wang H; Wang T; Hu X; Deng C; Jiang J; Qin H; Dong K; Chen S; Jin C; Zhao Q; Du B; Hu P
    Br J Clin Pharmacol; 2022 Sep; 88(9):4111-4120. PubMed ID: 35373389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.
    Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E
    Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.